Magle Group Issues Profit Warning Ahead of Q4 and Full-Year 2025 Results
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026.
This follows the Group’s strategic refocus announced on January 29, 2026, in which Magle Group outlined a renewed commitment to profitability, operational discipline, and long-term value creation. As part of this transformation, the Company is conducting a comprehensive operational review, which includes the impairment of non-core assets, streamlining of operations, and realignment of its portfolio.
Preliminary Financial Expectations for Q4 and FY 2025
The Company expects to report:
- Full-year 2025 Revenue of approximately 300 MSEK (compared to 256 MSEK in 2024)
- Q4 2025 Revenue of approximately 85 MSEK (compared to 84 MSEK in 2024)
- Full-year 2025 EBITDA of approximately negative 10 MSEK (compared to 59 MSEK in 2024)
- Q4 2025 EBITDA of approximately negative 42 MSEK (compared to 20 MSEK in 2024), reflecting restructuring costs, impairments, and asset write-downs
These figures are unaudited and subject to finalisation ahead of the formal reporting date.
Aaron Wong, Interim Chief Executive Officer, commented:
“The short-term financial impact we are announcing today is the direct consequence of decisive action. We are simplifying the business, shedding complexity, and focusing on our most scalable and profitable segments - Magle Biopolymers and Magle Chemoswed. These measures, while painful in the near term, will enable stronger, more sustainable performance moving forward.”
Key Drivers of the Profit Warning
- Impairment of early-stage biotech assets and pipeline projects that are no longer aligned with Magle Group’s core strategy;
- Restructuring and redundancy costs associated with operational consolidation and organisational realignment;
- Inventory write-downs and exit costs from discontinued or deprioritised business lines.
These are primarily non-recurring, non-cash charges and reflect a strategic commitment to sharpening commercial focus and improving capital efficiency.
Forward Strategy
The Group will now prioritise revenue generation from its Biopolymer and CDMO businesses, with a disciplined approach to R&D and capital allocation. Future innovation will be tightly linked to commercial readiness and scalability.
A stakeholder Q&A and strategy session with Interim CEO Aaron Wong will be scheduled following the Q4 2025 report to ensure transparency and alignment with the Group’s forward-looking priorities.